Urogen Pharma Ltd (URGN)

01:53 AM

Is UroGen Pharma Ltd. a good long term investmentFree Popular Stock Recommendations - PrintWeekIndia

01:53 AM

01:34 AM

What analysts say about UroGen Pharma Ltd. stockExplosive trading growth - PrintWeekIndia

01:34 AM

Jul 24, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future - Yahoo Finance

Jul 24, 2025

Jul 23, 2025

UroGen Pharma Ltd. Stock Analysis and ForecastTriple-digit wealth increases - Autocar Professional

Jul 23, 2025

Jul 22, 2025

What drives UroGen Pharma Ltd. stock priceFree Risk Assessment Services - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire

Jul 22, 2025

Jul 22, 2025

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire

Jul 22, 2025

Jul 21, 2025

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit - GlobeNewswire Inc.

Jul 21, 2025

Jul 21, 2025

UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study - Nasdaq

Jul 21, 2025

Jul 21, 2025

UroGen Pharma (URGN) Reports Long-term Results for Bladder Cance - GuruFocus

Jul 21, 2025

Jul 21, 2025

UroGen’s bladder cancer drug shows durable response in long-term study - Investing.com Australia

Jul 21, 2025

Jul 21, 2025

UroGen Pharma Announces Long-Term Efficacy Results of ZUSDURI for Non-Muscle Invasive Bladder Cancer in Clinical Genitourinary Cancer Journal - Quiver Quantitative

Jul 21, 2025

Jul 21, 2025

UroGen Announces Five-Year Long-Term Extension Study of the - GlobeNewswire

Jul 21, 2025

Jul 21, 2025

Breakthrough: New Bladder Cancer Treatment Maintains Effectiveness for 3.5 Years Without Surgery - Stock Titan

Jul 21, 2025

Jul 20, 2025

2025-07-20 | URGN Shareholders Have Opportunity to Lead UroGen Pharma Ltd. Class Action LawsuitContact Bronstein, Gewirtz and Grossman, LLC Today! | NDAQ:URGN | Press Release - Stockhouse

Jul 20, 2025

Jul 19, 2025

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors - GlobeNewswire

Jul 19, 2025

Jul 19, 2025

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 19, 2025

Jul 18, 2025

UroGen Bets Big On Gel-Based Cancer Treatments - Finimize

Jul 18, 2025

Jul 17, 2025

URGN Class Action News: UroGen Pharma Ltd. Investors with - GlobeNewswire

Jul 17, 2025

Jul 17, 2025

2025-07-17 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse

Jul 17, 2025

Jul 16, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming DeadlinesURGN - ETX View

Jul 16, 2025

Jul 15, 2025

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors - GlobeNewswire

Jul 15, 2025

Jul 15, 2025

What makes UroGen Pharma Ltd. stock price move sharplyBreakout Setup Scanner - beatles.ru

Jul 15, 2025

Jul 14, 2025

2025-07-14 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse

Jul 14, 2025

Jul 13, 2025

What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛

Jul 13, 2025

Jul 12, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 12, 2025

Jul 12, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire

Jul 12, 2025

Jul 12, 2025

Urogen Pharma's (URGN) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jul 12, 2025

Jul 11, 2025

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire

Jul 11, 2025